AXDX — Accelerate Diagnostics Share Price
0.000.00%
Last trade - 00:00- $28.05m
- $65.30m
- $12.06m
- 23
- 24
- 42
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -265.82% | ||
| Return on Equity | n/a | ||
| Operating Margin | -313.77% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.3 | 11.16 | 11.78 | 12.75 | 12.06 | 11.9 | 12.3 | 16.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.
Directors
- John Patience CHM (73)
- John Phillips PRE (55)
- Steve Reichling CFO (42)
- Ron Price OTH (57)
- Wayne Burris DRC
- Hany Massarany DRC (59)
- Thomas Brown IND (73)
- Louise Francesconi IND (68)
- Mark Miller IND (65)
- Jack Schuler IND (80)
- Matthew Strobeck IND (48)
- Frank Ten Brink IND (64)
- Charles Watts IND (78)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- December 24th, 2012
- Public Since
- October 27th, 1993
- No. of Shareholders
- 33
- No. of Employees
- 134
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 25,043,822
- Address
- SUITE 108, 303 E 17TH AVE, DENVER, 80203
- Web
- https://acceleratediagnostics.com/
- Phone
- +1 3038638088
- Auditors
- Ernst & Young LLP
Upcoming Events for AXDX
Accelerate Diagnostics Inc Annual Shareholders Meeting
Q1 2025 Accelerate Diagnostics Inc Earnings Release
Q2 2025 Accelerate Diagnostics Inc Earnings Release
Similar to AXDX
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Alpha Tau Medical
NASDAQ Capital Market
FAQ
What is the Accelerate Diagnostics share price?
As of Today at 18:03 UTC, shares in Accelerate Diagnostics are trading at $1.12. This share price information is delayed by 15 minutes.
How has the Accelerate Diagnostics share price performed this year?
Shares in Accelerate Diagnostics last closed at $1.12 and the price had moved by +3.7% over the past 365 days. In terms of relative price strength the Accelerate Diagnostics share price has underperformed the S&P500 Index by -7.92% over the past year.
What are the analyst and broker recommendations for Accelerate Diagnostics?
The overall consensus recommendation for Accelerate Diagnostics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Accelerate Diagnostics dividend yield?
Accelerate Diagnostics does not currently pay a dividend.
Does Accelerate Diagnostics pay a dividend?
Accelerate Diagnostics does not currently pay a dividend.
When does Accelerate Diagnostics next pay dividends?
Accelerate Diagnostics does not currently pay a dividend.
How do I buy Accelerate Diagnostics shares?
To buy shares in Accelerate Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Accelerate Diagnostics?
As of the previous close price of $1.12, shares in Accelerate Diagnostics had a market capitalisation of $28.05m.
Where are Accelerate Diagnostics shares listed?
Here are the trading details for Accelerate Diagnostics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AXDX
What kind of share is Accelerate Diagnostics?
Based on an overall assessment of its quality, value and momentum Accelerate Diagnostics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Accelerate Diagnostics share price forecast for 2025?
The analyst consensus target price for shares in Accelerate Diagnostics is $1.50. That is 33.93% above the last closing price of $1.12.
Analysts covering Accelerate Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of -$2.30 for the next financial year.
Find out moreWhat is the trend in the Accelerate Diagnostics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Accelerate Diagnostics. Over the past six months, its share price has underperformed the S&P500 Index by -38.62%.
As of the last closing price of $1.12, shares in Accelerate Diagnostics were trading -22.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Accelerate Diagnostics PE Ratio?
The Accelerate Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Accelerate Diagnostics?
Accelerate Diagnostics' management team is headed by:
- John Patience - CHM
- John Phillips - PRE
- Steve Reichling - CFO
- Ron Price - OTH
- Wayne Burris - DRC
- Hany Massarany - DRC
- Thomas Brown - IND
- Louise Francesconi - IND
- Mark Miller - IND
- Jack Schuler - IND
- Matthew Strobeck - IND
- Frank Ten Brink - IND
- Charles Watts - IND